{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:20:11Z","timestamp":1780536011902,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s12185-019-02707-w","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T06:02:50Z","timestamp":1563343370000},"page":"406-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas"],"prefix":"10.1007","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-0195","authenticated-orcid":false,"given":"Silvana","family":"Novelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Monter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pilar Garc\u00eda-Muret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Briones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,17]]},"reference":[{"issue":"4","key":"2707_CR1","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1309\/AJCPOBDP2OQAJ5BR","volume":"139","author":"SX Song","year":"2013","unstructured":"Song SX, Willemze R, Swerdlow SH, Kinney MC, Said JW. Mycosis fungoides. Am J Clin Pathol. 2013;139(4):466\u201390 (Internet).","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"2707_CR2","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"E Olsen","year":"2007","unstructured":"Olsen E, Vonderheid E, Pimpinelli N. Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713\u201323.","journal-title":"Blood"},{"issue":"11","key":"2707_CR3","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/ajh.22139","volume":"86","author":"RA Wilcox","year":"2011","unstructured":"Wilcox RA. Cutaneous T cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86(11):928\u201348.","journal-title":"Am J Hematol"},{"key":"2707_CR4","first-page":"857","volume":"139","author":"Y Kim","year":"2003","unstructured":"Kim Y. Long-term outcome of 525 Patients with mycosis fungoides and s\u00e9zary syndrome. Arch Dermatol. 2003;139:857\u201366.","journal-title":"Arch Dermatol"},{"issue":"8","key":"2707_CR5","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/bmt.2015.6","volume":"50","author":"A Sureda","year":"2015","unstructured":"Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transpl. 2015;50(8):1037\u201356.","journal-title":"Bone Marrow Transpl"},{"issue":"31","key":"2707_CR6","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","volume":"28","author":"NS Agar","year":"2010","unstructured":"Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730\u20139.","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"2707_CR7","first-page":"630","volume":"29","author":"R Willemze","year":"2018","unstructured":"Willemze R, Dreyling M. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):630\u201340.","journal-title":"Ann Oncol"},{"issue":"6","key":"2707_CR8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/sj.bmt.1704411","volume":"33","author":"S Ingen-Housz-Oro","year":"2004","unstructured":"Ingen-Housz-Oro S, Bachelez H, Verola O, Lebb\u00e9 C, Marolleau JP, Hennequin C, et al. High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma. Bone Marrow Transpl. 2004;33(6):629\u201334.","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"2707_CR9","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","volume":"26","author":"C Hosing","year":"2015","unstructured":"Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015;26(12):2490\u20135.","journal-title":"Ann Oncol"},{"issue":"29","key":"2707_CR10","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","volume":"28","author":"RF Duarte","year":"2010","unstructured":"Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a retrospective analysis of the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2010;28(29):4492\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2707_CR11","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912\u20139.","journal-title":"Blood"},{"issue":"8","key":"2707_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2008-05-154609","volume":"112","author":"SO Arulogun","year":"2008","unstructured":"Arulogun SO, Prince HM, Ng J, Lade S, Ryan GF, Blewitt O, et al. Long-term outcomes of patients with advanced-stage cutaneous T cell lymphoma and large cell transformation. Blood. 2008;112(8):1\u20133.","journal-title":"Blood"},{"issue":"4","key":"2707_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jaad.2011.12.011","volume":"67","author":"JL Herrmann","year":"2012","unstructured":"Herrmann JL, Hughey LC. Recognizing large-cell transformation of mycosis fungoides. J Am Acad Dermatol. 2012;67(4):665\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"2707_CR14","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","volume":"119","author":"MF Benner","year":"2012","unstructured":"Benner MF, Jansen PM, Vermeer MH, Willemze R. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood. 2012;119(7):1643\u20139.","journal-title":"Blood"},{"issue":"4","key":"2707_CR15","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1182\/blood.V92.4.1150","volume":"92","author":"E Diamandidou","year":"1998","unstructured":"Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R. Transformation of mycosis fungoides\/sezary syndrome: clinical characteristics and prognosis. Blood. 1998;92(4):1150\u20139.","journal-title":"Blood"},{"issue":"7","key":"2707_CR16","first-page":"2212","volume":"95","author":"B Vergier","year":"2000","unstructured":"Vergier B, de Muret A, Beylot-Barry M, Vaillant L, Ekouevi D, Chene G, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French study group of cutaneious lymphomas. Blood. 2000;95(7):2212\u20138.","journal-title":"Blood"},{"issue":"1","key":"2707_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","volume":"125","author":"CFM Hughes","year":"2015","unstructured":"Hughes CFM, Khot A, Mccormack C, Lade S, Westerman DA, Twigger R, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy. Blood. 2015;125(1):71\u201382.","journal-title":"Blood"},{"key":"2707_CR18","unstructured":"European Medicines Agency\u2013EMA. Annex I summary of product characteristics\u2013ADCETRIS. 2018;1\u201347. Available from: \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002455\/WC500135055.pdf\n                    \n                  . Accessed 27 Oct 2018."},{"issue":"Suppl 1","key":"2707_CR19","first-page":"1509","volume":"130","author":"SM Horwitz","year":"2017","unstructured":"Horwitz SM, Scarisbrick JJ, Dummer R, Duvic M, Kim YH, Walewski J, et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T cell lymphoma (CTCL). Blood. 2017;130(Suppl 1):1509.","journal-title":"Blood"},{"issue":"2","key":"2707_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3109\/09546634.2015.1086479","volume":"27","author":"S Novelli","year":"2016","unstructured":"Novelli S, Garc\u00eda-Muret P, Sierra J, Briones J. Alemtuzumab treatment for S\u00e9zary syndrome: a single-center experience. J Dermatol Treat. 2016;27(2):179\u201381.","journal-title":"J Dermatol Treat"},{"issue":"6","key":"2707_CR21","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3324\/haematol.11127","volume":"92","author":"MG Bernengo","year":"2007","unstructured":"Bernengo MG, Quaglino P, Comessatti A, Ortoncelli M, Novelli M, Lisa F, et al. Low-dose intermittent alemtuzumab in the treatment of S\u00e9zary syndrome: clinical and immunologic findings in 14 patients. Haematologica. 2007;92(6):784\u201394.","journal-title":"Haematologica"},{"key":"2707_CR22","unstructured":"European Medicines Agency\u2013EMA. Annex I summary of product characteristics\u2013POTELIGEO. 2018; p 1. \n                    https:\/\/www.ema.europa.eu\/documents\/smop-initial\/chmp-summary-positive-opinion-poteligeo_en.pdf\n                    \n                  . Accessed 27 Oct 2018."},{"issue":"5","key":"2707_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/intimm\/dxp019","volume":"21","author":"T Kondo","year":"2009","unstructured":"Kondo T, Takiguchi M. Human memory CCR23\u2009+\u2009CD8\u2009+\u2009T cell subset has the ability to produce multiple cytokines. Int Immunol. 2009;21(5):523\u201332.","journal-title":"Int Immunol"},{"issue":"3","key":"2707_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1084\/jem.20020399","volume":"196","author":"P Hoffmann","year":"2002","unstructured":"Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4+ CD25+ regulatory T Cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389\u201399.","journal-title":"J Exp Med"},{"issue":"5","key":"2707_CR25","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/bmt.2015.315","volume":"51","author":"Y Inoue","year":"2016","unstructured":"Inoue Y, Fuji S, Tanosaki R, Fukuda T. Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality. Bone Marrow Transpl. 2016;51(5):725\u20137.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"2707_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3960\/jslrt.56.135","volume":"56","author":"N Kawano","year":"2017","unstructured":"Kawano N, Kuriyama T, Yoshida S, Kawano S, Yamano Y, Marutsuka K, et al. The impact of a humanized CCR26 antibody (Mogamulizumab) on patients with aggressive-type adult T cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation. J Clin Exp Hematop. 2017;56(3):135\u201344.","journal-title":"J Clin Exp Hematop"},{"issue":"9","key":"2707_CR27","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/annonc\/mdx274","volume":"28","author":"A Le Bourgeois","year":"2017","unstructured":"Le Bourgeois A, Labopin M, Blaise D, Ceballos P, Vigouroux S, de Latour R Peffault, et al. Reduced-intensity versus reduced-toxicity myeloablative fludarabine\/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire. Ann Oncol. 2017;28(9):2191\u20138.","journal-title":"Ann Oncol"},{"issue":"2\u20133","key":"2707_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.trim.2011.06.008","volume":"25","author":"M Schlaak","year":"2011","unstructured":"Schlaak M, Kurschat P, Shimabukuro-Vornhagen A, Scheid C, Chemnitz J, Stadler R, et al. Donor lymphocyte infusions combined with systemic PUVA\/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation. Transpl Immunol. 2011;25(2\u20133):163\u20136.","journal-title":"Transpl Immunol"},{"issue":"8","key":"2707_CR29","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.3109\/10428194.2016.1167204","volume":"57","author":"J Montoro","year":"2016","unstructured":"Montoro J, Sanz J, Sanz GF, Sanz MA. Advances in haploidentical stem cell transplantation for hematologic malignancies. Leuk Lymphoma. 2016;57(8):1766\u201375.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2707_CR30","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.bbmt.2017.11.030","volume":"24","author":"J Mariotti","year":"2018","unstructured":"Mariotti J, Devillier R, Bramanti S, Sarina B, Furst S, Granata A, et al. T Cell-replete haploidentical transplantation with post-transplantation cyclophosphamide for Hodgkin lymphoma relapsed after autologous transplantation: reduced incidence of relapse and of chronic graft-versus-host disease compared with Hla-identical rela. Biol Blood Marrow Transpl. 2018;24(3):627\u201332.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"2707_CR31","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","volume":"127","author":"AS Kanate","year":"2016","unstructured":"Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127(7):938\u201347.","journal-title":"Blood"},{"issue":"6","key":"2707_CR32","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","volume":"39","author":"L Luznik","year":"2012","unstructured":"Luznik L, O\u2019Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39(6):683\u201393.","journal-title":"Semin Oncol"},{"issue":"1","key":"2707_CR33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","volume":"25","author":"A Ijaz","year":"2019","unstructured":"Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, et al. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transpl. 2019;25(1):94\u20139.","journal-title":"Biol Blood Marrow Transpl."},{"issue":"10","key":"2707_CR34","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1038\/bmt.2017.158","volume":"52","author":"Y Oshima","year":"2017","unstructured":"Oshima Y, Tanimoto T, Yuji K, Tojo A. Association between GvHD and nivolumab in the FDA adverse event reporting system. Bone Marrow Transpl. 2017;52(10):1463\u20134.","journal-title":"Bone Marrow Transpl"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02707-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02707-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02707-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T23:44:35Z","timestamp":1594856675000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02707-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,17]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["2707"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02707-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,17]]},"assertion":[{"value":"1 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}},{"value":"The authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}